Trial Profile
A Study to Assess the Effect of MK-7264 (AF-219) on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Therapeutic Use
- Acronyms Cough Challenge
- Sponsors Afferent Pharmaceuticals
- 25 Apr 2019 Primary endpoint has been not met. (Cough Reflex Sensitivity to Distilled Water inducing at least 5 coughs (C5) in Healthy Volunteers Who Received Gefapixant 100 mg and Placebo (Period 1 & Period 2 Combined)), as per results published in the European Respiratory Journal.
- 25 Apr 2019 Primary endpoint has been met. (Cough Reflex Sensitivity to Distilled Water inducing at least 2 coughs (C2) in Healthy Volunteers Who Received Gefapixant 100 mg and Placebo (Period 1 & Period 2 Combined)), as per results published in the European Respiratory Journal.
- 25 Apr 2019 Primary endpoint has been met. (Cough Reflex Sensitivity to Distilled Water in chronic cough Patients Who Received Gefapixant 100 mg and Placebo (Period 1 & Period 2 Combined)), as per results published in the European Respiratory Journal.